Full video transcriptClick to expand
Auto-generated transcript of @celinaestrada64's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:01So here's an update I did not think I'd be making so soon, but we got a refill!
- 0:09So I am... I stopped on week 19 and because I wasn't on the injection for the last two weeks,
- 0:17we are on week 20 of actually being on the injection.
- 0:20So for week 20, I am currently a hundred and seventy pounds.
- 0:28So I did gain, I think it was like six pounds since the last time I took it.
- 0:37So I gained six pounds, I'm at a hundred and seventy pounds.
- 0:44We'll see how this goes. I went straight into the three milligrams.
- 0:48We're just gonna go put a lot into it and see where that takes us.
- 0:55But last three, the last two weeks, I literally built my body slowly wanting to eat more,
- 1:06which really sucks. That first week, I think I still have like a very small appetite.
- 1:13There are certain things that I can't, I still can't eat a lot of, but I slowly realized that I am eating a lot more than what I would normally eat.
- 1:23So I'm hoping that we can start back into cutting down what I eat.
- 1:27It's now at 11 o'clock in the morning and I'm hungry.
- 1:31Instead of it being like four o'clock and I'm hungry.
- 1:35So I've noticed the big difference or like when I wake up, it's like, okay, I have to have something to eat for breakfast because I'm hungry now.
- 1:41Whereas normally it's like I'm not hungry, I can't even finish off my coffee.
- 1:45So I have noticed a lot of differences ever since I stopped the injection two weeks ago.
- 1:50So hopefully the injection will kick in.
- 1:54Like it did last time, last time I have a week off of it and I lost, I think it was like six pounds within that first week.
- 2:02So I'm hoping that because we did take two weeks off, it'll kind of kick start again like it did last time.
- 2:10But we'll see. I will keep you guys updated. I'll probably do another video next week on Monday and see where we're at then.
- 2:17But as of right now, that's where we are.
- 2:20I will post before and after pictures after the video.
- 2:22So you guys can kind of see one of the differences that I am still going to the gym.
- 2:25Although I haven't gone as much as I would like.
- 2:28I need to start that back up again because I think I've only done like once or twice a week if that.
- 2:34So we got to start that back up again and kick ourselves in the butt and keep going.
- 2:39So we'll see where this goes.
Saxenda refill excitement: what the GLP-1 hype misses
Quick answer
Celina is documenting a two-week liraglutide (Saxenda) interruption followed by restart at 3 mg, during which she gained approximately six pounds and experienced rapid return of appetite, including morning hunger and increased meal frequency. These observations are consistent with liraglutide's short half-life of roughly 13 hours and the well-documented rebound hunger seen in GLP-1 discontinuation studies. The expectation of a post-restart 'kickstart' effect is not supported by clinical evidence and should be discussed with her prescribing provider.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Saxenda refill excitement: what the GLP-1 hype misses, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Saxenda refill excitement: what the GLP-1 hype misses is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Saxenda refill excitement: what the GLP-1 hype misses" from Celina Estrada. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Celina is documenting a two-week liraglutide (Saxenda) interruption followed by restart at 3 mg, during which she gained approximately six pounds and experienced rapid return of appetite, including morning hunger and increased meal frequency.
The reason this review is not generic is the source wording and the canonical claim label "glp1 ahh we got a refil i wasnt expecting it at all to be honest." In this clip, the useful excerpt is: "So here's an update I did not think I'd be making so soon, but we got a refill!" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Celina is documenting a two-week liraglutide (Saxenda) interruption followed by restart at 3 mg, during which she gained approximately six pounds and experienced rapid return of appetite, including morning hunger and increased meal frequency.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Celina is documenting a two-week liraglutide (Saxenda) interruption followed by restart at 3 mg, during which she gained approximately six pounds and experienced rapid return of appetite, including morning hunger and increased meal frequency. These observations are consistent with liraglutide's short half-life of roughly 13 hours and the well-documented rebound hunger seen in GLP-1 discontinuation studies. The expectation of a post-restart 'kickstart' effect is not supported by clinical evidence and should be discussed with her prescribing provider.
- Liraglutide has a half-life of roughly 13 hours, meaning appetite suppression can reverse within 2-3 days of stopping, which matches what Celina described experiencing.
- A 2022 Wilding et al. study in Diabetes, Obesity and Metabolism found patients regained about two-thirds of lost weight within one year of stopping a GLP-1 agonist, making her six-pound regain unsurprising.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Liraglutide has a half-life of roughly 13 hours, meaning appetite suppression can reverse within 2-3 days of stopping, which matches what Celina described experiencing.
- A 2022 Wilding et al. study in Diabetes, Obesity and Metabolism found patients regained about two-thirds of lost weight within one year of stopping a GLP-1 agonist, making her six-pound regain unsurprising.
- The SCALE Maintenance trial (Davies et al., 2021, The Lancet) confirmed that stopping liraglutide leads to significantly more weight regain than continuing, reinforcing the case for continuous supervised use.
- There is no clinical evidence that a planned medication gap creates a 'kickstart' effect on restart. Early weight loss in GLP-1 therapy reflects initial deficit and fluid shifts, not drug novelty.
- A 2023 meta-analysis by Zhao et al. in Obesity Reviews found adding structured exercise to GLP-1 therapy improved body composition beyond medication alone, supporting her plan to return to the gym.
- Restarting Saxenda after any interruption longer than a few days should be discussed with a prescribing provider, as re-titration guidance varies and skipping titration steps can increase side effect risk.
- Appetite returning quickly after stopping a GLP-1 medication is biology, not a personal failure. The drug suppresses hunger pharmacologically, and that effect ends when the drug clears.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @celinaestrada64 actually say?
After a two-week break from Saxenda (liraglutide), Celina gained roughly six pounds and noticed her appetite returning fast. She restarted at 3 mg and is hoping the medication will "kick in like it did last time" and produce rapid early weight loss again. She also mentioned eating more, waking up hungry, and feeling the difference in appetite regulation within days of stopping the injection.
This is a pretty honest account of what stopping a GLP-1 receptor agonist actually feels like. She is not selling anything or overclaiming. She is tracking her own experience week by week, which is more transparency than you get from most weight loss content on this platform.
Does the science back this up?
Yes, and it is not subtle. The appetite return she describes is well-documented in clinical literature, and the weight regain trajectory is consistent with what trials show.
A 2022 paper by Wilding et al. in Diabetes, Obesity and Metabolism followed patients after stopping semaglutide (a closely related GLP-1 agonist) and found that participants regained about two-thirds of their lost weight within a year of discontinuation. That is a different drug, but the mechanism is shared: GLP-1 receptor agonists suppress appetite pharmacologically, and when the drug clears, the suppression clears with it.
Liraglutide (Saxenda) has a half-life of roughly 13 hours, meaning it clears the system in two to three days. The 2021 SCALE Maintenance trial (Davies et al., The Lancet) showed that patients who stopped liraglutide after a run-in period regained significantly more weight than those who continued. Hunger returning within days of stopping, as Celina experienced, is physiologically expected, not a personal failure.
What did they get wrong (or right)?
The claim that earned the most scrutiny here is the idea that taking two weeks off might "kickstart" weight loss the way a one-week break apparently did before. That is not really how liraglutide works, and expecting a restart bonus is not supported by evidence.
Weight loss with GLP-1 agonists tends to follow a dose-response curve and a time curve. The early weeks often show faster loss partly because of fluid shifts and caloric deficit novelty, not because the drug is freshest. Restarting after a gap does not reset those mechanisms. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed weight loss was progressive and sustained with continuous use, not cyclical.
What she got right: the observation that appetite suppression fades fast after stopping is accurate. Her description of hunger timing shifting from 4 PM back to the morning is a real clinical signal, not placebo. She also correctly noted she went back to 3 mg, though we cannot comment on whether that dose is clinically appropriate for her specifically since that is a provider decision.
What should you actually know?
If you are on a GLP-1 medication and you stop, even briefly, expect appetite to return and expect some weight regain. This is biology, not willpower failure. The drug is doing what it is supposed to do pharmacologically, and when it is gone, so is that effect.
A few things worth knowing if you are following a similar journey. First, the "kickstart" concept is not validated. Restarting a medication after a gap is not equivalent to first starting it. Second, GLP-1 medications are generally intended for continuous use under medical supervision, not on-and-off cycling. Stopping and starting without guidance can complicate titration and side effect management. Third, the combination of medication plus exercise that Celina mentions has real support: a 2023 meta-analysis by Zhao et al. in Obesity Reviews found that adding structured exercise to GLP-1 therapy improved body composition outcomes beyond medication alone. Getting back to the gym, as she plans to, is genuinely useful, not just motivational filler.
Her experience is real. The science behind it is clear. The "kickstart" framing is the one part that deserves a skeptical read.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Celina Estrada · TikTok creator
19.3K views on this video
Ahh we got a refil!!! I wasnt expecting it at all to be honest but in so glad I was able to get a months worth 🙌🏼 #saxenda #saxendaweightlossjourney #weightlossjourney #weightloss #weightlossprogress #saxendasuccess #saxendaupdate
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about liraglutide has a half-life of roughly 13 hours, meaning appetite?
Liraglutide has a half-life of roughly 13 hours, meaning appetite suppression can reverse within 2-3 days of stopping, which matches what Celina described experiencing.
What does the video say about a 2022 wilding et al. study in diabetes, obesity?
A 2022 Wilding et al. study in Diabetes, Obesity and Metabolism found patients regained about two-thirds of lost weight within one year of stopping a GLP-1 agonist, making her six-pound regain unsurprising.
What does the video say about the scale maintenance trial (davies et al., 2021, the lancet)?
The SCALE Maintenance trial (Davies et al., 2021, The Lancet) confirmed that stopping liraglutide leads to significantly more weight regain than continuing, reinforcing the case for continuous supervised use.
What does the video say about there?
There is no clinical evidence that a planned medication gap creates a 'kickstart' effect on restart. Early weight loss in GLP-1 therapy reflects initial deficit and fluid shifts, not drug novelty.
What does the video say about a 2023 meta-analysis by zhao et al. in obesity reviews?
A 2023 meta-analysis by Zhao et al. in Obesity Reviews found adding structured exercise to GLP-1 therapy improved body composition beyond medication alone, supporting her plan to return to the gym.
What does the video say about restarting saxenda after any interruption longer than a few days?
Restarting Saxenda after any interruption longer than a few days should be discussed with a prescribing provider, as re-titration guidance varies and skipping titration steps can increase side effect risk.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Celina Estrada, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.